Does the cancer patient want to know? Results from a study in an Indian tertiary cancer center.

South Asian J Cancer

Department of Palliative Care, Bhagwan Mahaveer Cancer Hospital, JLN Marg, Malviya Nagar, Jaipur, India.

Published: April 2013

Objective: The disclosure of the diagnosis of cancer is a distressing and complex issue. Families and doctors still do not tell patients when they have cancer in the belief that the patient does not want to know and telling him would lead to fear and depression. The aim of this survey was to evaluate the information needs of Indian cancer patients.

Materials And Methods: A cross-sectional survey of 300 patients' views was conducted with the help of an adaptation of Cassileth's Information Needs questionnaire.

Results: A majority of cancer patients exhibited a strong need for information about illness and treatment. Ninety-four percent wanted to know if their illness was cancer. Most patients also wanted to know the chance of cure (92%). Age, education, and type of treatment significantly affect information preferences. Gender did not have an effect on information needs.

Conclusion: This study showed that most of the patients wanted to know about their illness, treatment, side-effects, and chances of cure.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876664PMC
http://dx.doi.org/10.4103/2278-330X.110487DOI Listing

Publication Analysis

Top Keywords

cancer patients
8
illness treatment
8
wanted illness
8
patients wanted
8
cancer
7
cancer patient
4
patient know?
4
know? study
4
study indian
4
indian tertiary
4

Similar Publications

Background: Kidney tumors, common in the urinary system, have widely varying survival rates post-surgery. Current prognostic methods rely on invasive biopsies, highlighting the need for non-invasive, accurate prediction models to assist in clinical decision-making.

Purpose: This study aimed to construct a K-means clustering algorithm enhanced by Transformer-based feature transformation to predict the overall survival rate of patients after kidney tumor resection and provide an interpretability analysis of the model to assist in clinical decision-making.

View Article and Find Full Text PDF

Validity of one-time phantomless patient-specific quality assurance in proton therapy with regard to the reproducibility of beam delivery.

Med Phys

January 2025

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany.

Background: Patient-specific quality assurance (PSQA) is a crucial yet resource-intensive task in proton therapy, requiring special equipment, expertise and additional beam time. Machine delivery log files contain information about energy, position and monitor units (MU) of all delivered spots, allowing a reconstruction of the applied dose. This raises the prospect of phantomless, log file-based QA (LFQA) as an automated replacement of current phantom-based solutions, provided that such an approach guarantees a comparable level of safety.

View Article and Find Full Text PDF

Background: Diffusing alpha-emitters Radiation Therapy ("Alpha DaRT") is a promising new radiation therapy modality for treating bulky tumors. Ra-carrying sources are inserted intratumorally, producing a therapeutic alpha-dose region with a total size of a few millimeter via the diffusive motion of Ra's alpha-emitting daughters. Clinical studies of Alpha DaRT have reported 100% positive response (30%-100% shrinkage within several weeks), with post-insertion swelling in close to half of the cases.

View Article and Find Full Text PDF

Background: Anaplastic thyroid cancer (ATC) is a highly lethal disease, often diagnosed with advanced locoregional and distant metastases, resulting in a median survival of just 3-5 months. This study determines the stratified effectiveness of baseline treatments in all combinations, enabling precise prognoses prediction and establishing benchmarks for advanced therapeutic options.

Methods: The study extracted a cohort of pathologically confirmed ATC patients from the Surveillance, Epidemiology, and End Results program.

View Article and Find Full Text PDF

Background: Tumor size (TS) in pancreatic ductal adenocarcinoma (PDAC) is one of the most important prognostic factors. However, discrepancies between TS on preoperative images (TSi) and pathological specimens (TSp) have been reported. This study aims to evaluate the factors associated with the differences between TSi and TSp.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!